Nkarta (NKTX) Price & Analysis

Compare

680 Followers

NKTX Stock Chart & Stats

$2.41

-$0.05(-2.07%)

At close: Jan 08 4:00 PM EST

$2.41

-$0.05(-2.07%)

Day’s Range― - ―

52-Week Range$1.31 - $3.81

Previous CloseN/A

Volume369.36K

Average Volume (3M)1.05M

Market Cap

$171.17M

Enterprise Value-$88.34M

Total Cash (Recent Filing)$289.69M

Total Debt (Recent Filing)$78.54M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

Nov 05, 2025

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding71,024,510

10 Day Avg. Volume1,088,726

30 Day Avg. Volume1,054,667

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.52

Enterprise Value/Revenue-9.78

Enterprise Value/Gross Profit35.91

Enterprise Value/Ebitda0.71

Forecast

1Y Price Target

$12.40

Price Target Upside414.52% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentNkarta remains focused on executing NKX019’s clinical development in refractory autoimmune disease.

Financial PerformanceThe company finished the quarter with a cash & equivalents position of $334M, expected to provide operating runway into 2029.

Leadership And ExperienceAppointment of Shawn Rose as Chief Medical Officer and Head of Research and Development, who played a key role in the development of several approved medicines for autoimmune diseases.

Bears Say

Data InsightsThe data from Ntrust-1 and Ntrust-2 in H2:25 will likely be early and involve only a handful of patients per cohort, offering limited insights until more fulsome data in 2026.

Market CompetitionWithout a reduced lymphodepletion regimen, it is increasingly challenging to discern how NKX019 may be differentiated from other CD19 allogeneic cell therapies in the increasingly competitive market.

Nkarta News

Nkarta price target lowered to $12 from $14 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on Nkarta (NKTX) to $12 from $14 and keeps...

2M ago

NKTX

Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Nkarta today and set a price target of...

3M ago

NKTX

Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating

Analyst Gil Blum of Needham maintained a Buy rating on Nkarta, retaining the price target of $10.00. Gil...

3M ago

NKTX

Nkarta, Inc. Reports Q2 2025 Financial Results

Nkarta, Inc. ( ($NKTX) ) has released its Q2 earnings. Here is a breakdown of the information Nkarta,...

3M ago

NKTX

Strategic Positioning and Financial Stability Bolster Nkarta’s Biotech Prospects

TD Cowen analyst Yaron Werber has maintained their bullish stance on NKTX stock, giving a Buy rating on...

3M ago

NKTX

Nkarta reports Q2 EPS (31c), consensus (35c)

“We remain focused on the execution of our clinical trials and continue to believe in the differentiated potential...

3M ago

NKTX

Nkarta’s Innovative CAR-NK Cell Therapy Platform Drives Buy Rating

Nkarta, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C....

3M ago

NKTX

Nkarta price target lowered to $14 from $16 at Mizuho

Mizuho lowered the firm’s price target on Nkarta (NKTX) to $14 from $16 and keeps an Outperform rating...

5M ago

NKTX

Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel

Lyell Immunopharma (LYEL) announced the appointment of David Shook as CMO and Mark Meltz as general counsel and...

5M ago

LYEL

NKTX

Nkarta Announces Leadership Change with New CMO

Nkarta ( ($NKTX) ) just unveiled an update. On June 3, 2025, Nkarta announced the resignation of Dr....

5M ago

NKTX

Nkarta appoints Shawn Rose as CMO, head of R&D

Nkarta (NKTX) announced the appointment of Shawn Rose as its next Chief Medical Officer and Head of Research...

5M ago

NKTX

Nkarta’s Strategic Enhancements in NKX019 Program and Trial Expansion Drive Positive Buy Rating

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) on May 15...

5M ago

NKTX

Nkarta, Inc. Reports Q1 2025 Financial Results

Nkarta, Inc. ( ($NKTX) ) has released its Q1 earnings. Here is a breakdown of the information Nkarta,...

5M ago

NKTX

Nkarta downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Nkarta (NKTX) to Market Perform from Outperform without a price target The firm views the...

6M ago

NKTX

NKTX FAQ

What was Nkarta’s price range in the past 12 months?

Nkarta lowest stock price was $1.31 and its highest was $3.81 in the past 12 months.

What is Nkarta’s market cap?

Nkarta’s market cap is $171.17M.

When is Nkarta’s upcoming earnings report date?

Nkarta’s upcoming earnings report date is Nov 05, 2025 which is in 9 days.

How were Nkarta’s earnings last quarter?

Nkarta released its earnings results on Aug 12, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.355 by $0.045.

Is Nkarta overvalued?

According to Wall Street analysts Nkarta’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nkarta pay dividends?

Nkarta does not currently pay dividends.

What is Nkarta’s EPS estimate?

Nkarta’s EPS estimate is -0.31.

How many shares outstanding does Nkarta have?

Nkarta has 71,024,510 shares outstanding.

What happened to Nkarta’s price movement after its last earnings report?

Nkarta reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.355. Following the earnings report the stock price went up 12.755%.

Which hedge fund is a major shareholder of Nkarta?

Currently, no hedge funds are holding shares in NKTX

Nkarta Stock Smart Score

Outperform

Fundamentals

Return on Equity

-26.94%

Trailing 12-Months

Asset Growth

-19.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nkarta

Nkarta, Inc. (NKTX) is a biotechnology company that specializes in the development of engineered natural killer (NK) cell therapies to treat cancer. Operating in the biopharmaceutical sector, Nkarta leverages its proprietary platform to enhance the anti-tumor activity and persistence of NK cells. The company's core products are focused on innovative immuno-oncology treatments that harness the innate ability of NK cells to combat cancerous cells.

Nkarta (NKTX) Earnings & Revenues

Historic Earnings Reports

NKTX Stock 12 Month Forecast

Average Price Target

$12.40

▲(414.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,3.3230769230769233,4.546153846153846,5.76923076923077,6.992307692307692,8.215384615384616,9.438461538461539,10.661538461538461,11.884615384615385,13.107692307692309,14.330769230769231,15.553846153846154,16.77692307692308,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.8923076923076927,3.684615384615385,4.476923076923077,5.26923076923077,6.061538461538461,6.853846153846154,7.646153846153847,8.438461538461539,9.230769230769232,10.023076923076923,10.815384615384616,11.607692307692309,{"y":12.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.553846153846154,3.0076923076923077,3.4615384615384617,3.9153846153846157,4.36923076923077,4.823076923076924,5.276923076923078,5.730769230769232,6.184615384615386,6.63846153846154,7.092307692307694,7.546153846153846,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >